SC: Confirmation of an Auction Sale Does Not Bar Judicial Scrutiny of Reserve Price Valuation || Supreme Court Sets Aside Conviction of Four Men in a 1998 Gang Rape Case || Supreme Court: Privy Purse Privileges of Princely Rulers are Not Enforceable Legal Rights || Delhi HC: Repeated Court Summons May Distress and Re-Traumatize Child Sexual Assault Victims || Jammu and Kashmir High Court: Labeling Someone as a Terrorist Associate Amounts to Defamation || Delhi HC: Setting Aside or Altering a Judge’s Order by a Higher Court Doesn’t Affect Their Integrity || Delhi High Court: Accused Cannot be Faulted For Smart Replies; Interrogator Must be Sharper || Supreme Court: Belated Jurisdictional Challenge Impermissible After Participation in Arbitration || Supreme Court: Failure to Prove Specific Overt Acts of Each Unlawful Assembly Member Not Fatal || Supreme Court: Parental Salary Alone Cannot Determine OBC Creamy Layer Status

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :